Table 3.

Treatment of CRS and ICANS with siltuximab

At siltuximab administrationImprovement after siltuximab, %Median days to resolution (range)
CRS    
Treatment-naïve 28 82 (23/28) 1 (0-7) 
Tocilizumab-exposed∗  16 63 (10/16) 2 (0-4) 
Total 44 75 (33/44)  
ICANS    
Treatment-naïve†  13 69 (9/13) 3 (1-13) 
Steroid-exposed‡  17 53 (9/17) 5 (2-40) 
Total 30 60 (18/30)  
At siltuximab administrationImprovement after siltuximab, %Median days to resolution (range)
CRS    
Treatment-naïve 28 82 (23/28) 1 (0-7) 
Tocilizumab-exposed∗  16 63 (10/16) 2 (0-4) 
Total 44 75 (33/44)  
ICANS    
Treatment-naïve†  13 69 (9/13) 3 (1-13) 
Steroid-exposed‡  17 53 (9/17) 5 (2-40) 
Total 30 60 (18/30)  
∗

Patients who received ≥1 doses of tocilizumab before siltuximab.

†

Includes patients who received steroids at the same time as siltuximab or after siltuximab.

‡

Patients who received steroids for treatment of ICANS before siltuximab.

View Large